MMP9 and pulmonary arterial hypertension: Specifically, lipophilic statins used at concentrations ≥ 1 μM attenuated proliferation, promoted apoptosis and inhibited production of ET-1 and MMP-9, all of which are implicated in the pathogenesis of PAH and remodelling of pulmonary arteries.